Skip to main content
. 2008 Dec 3;89(1):391–399. doi: 10.3945/ajcn.2008.26363

FIGURE 3.

FIGURE 3

Fasting means (±SEMs) of plasma triacylglycerol (TG) concentrations after (pretreatment) and before (posttreatment) the fenofibrate intervention (3 wk, 160 mg/d) in the GOLDN (Genetics of Lipid Lowering Drugs and Diet Network) study participants (n = 844) according to the 3 GCKR-APOA5 combined genotype groups and hypertriglyceridemic (TG > 150 mg/dL) status. P, homozygous subjects for the wild-type alleles for each single-nucleotide polymorphism (SNP; CC rs780094 at the GCKR gene and TT −1131T→C APOA5 + CC 56C→G APOA5), n = 236; M, any mixed genotype not included in groups P and R, n = 490; and R, carriers of the variant allele for the GCKR rs780094 (CT or TT) and carriers of the variant alleles at one of the APOA5 SNPs (TC or CC at −1131T→C or CG or GG at 56C→G), n = 118. TG means were adjusted for sex, age, and BMI at pretreatment and additionally for baseline TG at the posttreatment analysis. P values indicate the global mean comparison among the 3 genotype groups in each category and time. NTG, normotriglyceridemia; HTG, hypertriglyceridemia.